Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
224 participants
INTERVENTIONAL
2024-12-06
2027-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This is an open-label, multi-national, multi-centre, randomised, single-period parallel study, involving a run-in period followed by a 26-week intervention period during which glucose levels will be controlled either by a fully closed-loop system or by participants usual insulin therapy with continuous glucose monitoring. A total of up to 224 adults with type 2 diabetes using insulin will be recruited through outpatient diabetes clinics, primary care centres, social media advertising and other established methods at participating centres. Participants will receive appropriate training in the safe use of the study devices.
The primary outcome is the between group difference in HbA1c at 26 weeks. Other key outcomes include the time spent with glucose levels within, above and below the target glucose range (3.9-10.0mmol/L) and mean sensor glucose as recorded by CGM over the 26 weeks. Insulin requirements, body weight, renal and liver function will also be compared. Safety evaluation comprises severe hypoglycaemic episodes, and other adverse and serious adverse events. Human factors outcomes include CGM \& closed-loop usage, questionnaires and semi-structured interviews.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Closed-loop in Adults With T2D Not Requiring Dialysis
NCT04701424
24/7 Closed-loop in Older Subjects With Type 1 Diabetes
NCT04025762
Closing the Loop in People with Type 1 Diabetes
NCT05653050
Closed-loop in Adults With T2D Requiring Dialysis
NCT04025775
Insulin Pump Versus Full Closed-loop for Type 2 Diabetes
NCT06959797
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
To determine the efficacy, safety and utility of fully closed-loop insulin delivery over 26 weeks in the home setting in adults with type 2 diabetes.
Study objectives:
To determine the efficacy, safety and utility of fully closed-loop insulin delivery over 26 weeks in the home setting in adults with type 2 diabetes.
1. EFFICACY: The objective is to assess the ability of fully closed-loop insulin delivery to improve glucose control as measured by HbA1c (primary endpoint) and sensor glucose metrics.
2. SAFETY: The objective is to evaluate the safety of fully closed-loop insulin delivery in terms of episodes and severity of hypoglycaemia, and nature and severity of other adverse events.
3. UTILITY: The objective is to determine the acceptability and duration of use of the CGM and closed-loop system.
4. HUMAN FACTORS: The objective is to assess cognitive, emotional, and behavioural characteristics of participants and their response to the closed-loop system using validated questionnaires and semi-structured interviews.
Participating clinical centres:
UK - Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust. - Imperial College Healthcare NHS Trust, London
\- Manchester Royal Infirmary, Manchester University NHS Foundation Trust
\- King's College Hospital, King's College Hospital NHS Foundation Trust, London
\- Guy's and St Thomas' NHS Foundation Trust
\- Norfolk and Norwich University Hospital, Norfolk and Norwich University Hospitals NHS Foundation Trust
\- University Hospitals of Leicester NHS Trust
Switzerland
\- Inselspital, Bern University Hospital, Bern
France
\- Centre Hospitalier Universitaire (CHU) de Toulouse
Germany
\- Medical Center - University of Freiburg
Austria
\- Medical University of Graz, Graz
Czech Republic
\- Diabetes Centre, Institute for Clinical and Experimental Medicine, Prague
Sample Size:
224 participants (112 per group) will be randomised. Recruitment will target a minimum quota of 25% of participants using basal insulin and a minimum quota of 60% of participants using multiple daily insulin injections.
Maximum duration of study for a subject: 30 weeks
Recruitment:
Participants will be recruited through outpatient diabetes clinics, primary care centres, social media advertising or other established methods at participating centres
Consent:
Participants will be asked to provide written informed consent.
Baseline Assessment:
Eligible participants will undergo baseline evaluation involving talking a medical history including demographics, height/weight, waist hip ratio and blood pressure measurement and blood samples for HbA1c, fasted lipid profile, renal and liver function. A urine albumin-creatinine ratio (ACR) will be performed, along with a urine pregnancy test in females of child-bearing age. Human factors questionnaires will be completed and a masked glucose sensor will be applied.
Run-in Period:
During a 2-3 week run-in period, participants will use their usual insulin therapy and wear a masked CGM system. At the end of the run-in period, for compliance, at least 10 days of CGM data needs to be recorded. CGM data during the run-in period will be used to assess baseline glucose control before the start of the intervention phase.
Randomisation:
Eligible participants will be randomised in a 1:1 ratio using central randomisation software to fully closed-loop or standard insulin therapy with CGM for 26 weeks. Randomisation will be stratified by site and baseline HbA1c.
Fully closed loop insulin delivery (intervention arm):
Following randomisation, participants in the closed-loop group will receive training on the study CGM, study insulin pump and closed-loop App during a 1-2 hour outpatient session. Competency on the use of the closed-loop system will be evaluated. Further training may be delivered as required. Participants will be advised to use the closed-loop system for the next 26 weeks.
Standard insulin therapy with CGM (control arm):
Following randomisation, participants in the control group will use their usual insulin therapy and the study CGM. Training on the use of the CGM will be provided. Participants will use standard insulin therapy and CGM for the next 26 weeks.
3 month study visit: Weight, waist hip ratio and blood pressure will be measured and a blood sample will be taken for measurement of HbA1c, fasted lipid profile, renal and liver function. Data from the closed-loop system and CGM system will be reviewed. Human factors questionnaires will be completed.
End of study assessments:
Weight, waist hip ratio and blood pressure will be measured and a blood sample will be taken for measurement of HbA1c, fasted lipid profile, renal and liver function. Urinary ACR will be measured. Human factors questionnaires will be completed and a subset of participants will participate in interviews. Study devices will be returned and participants will resume their usual insulin therapy and standard glucose monitoring.
Procedures for safety monitoring during trial:
Standard operating procedures for monitoring and reporting of all adverse events and adverse device events will be in place, including serious adverse events (SAE), serious adverse device effects (SADE) and specific adverse events (AE) such as severe hypoglycaemia.
A data safety and monitoring board (DSMB) will be informed of all serious adverse events and any unanticipated serious adverse device effects that occur during the study and will review compiled adverse event data at periodic intervals.
Criteria for withdrawal of subjects on safety grounds:
A participant may terminate participation in the study at any time without necessarily giving a reason and without any personal disadvantage. An investigator can stop the participation of a subject after consideration of the benefit/risk ratio. Possible reasons are:
* Participant is unable to demonstrate safe use of study devices as judged by the investigator
* Serious adverse events
* Significant protocol violation or non-compliance
* Decision by the investigator, or the Sponsor, that termination is in the participant's best medical interest
* Pregnancy, planned pregnancy, or breast feeding
* Allergic reaction to insulin or severe allergic reaction to adhesive surface of infusion set or glucose sensor
* Technical grounds (e.g. participant relocates)
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Fully closed-loop insulin delivery (CamAPS HX)
The automated closed loop system (CamAPS FX) will consist of:
* YpsoPump insulin pump (Ypsomed, Burgdorf, Switzerland)
* FreeStyle Libre 3 glucose sensor (Abbott Diabetes Care, CA, USA)
* Smartphone hosting CamAPS HX app with the Cambridge model predictive control algorithm
* Cloud upload system to review CGM/insulin data.
Participants will use the fully closed-loop system for 26 weeks at home
CamAPS HX
The automated closed loop system (CamAPS HX) will consist of:
YpsoPump insulin pump Freestyle Libre 3 glucose sensor Smartphone hosting CamAPS HX app with the Cambridge model predictive control algorithm
Standard insulin therapy with glucose sensor
Usual insulin therapy and FreeStyle Libre 3 glucose sensor (Abbott Diabetes Care, CA, USA) for 26 weeks at home.
Standard insulin therapy with glucose sensor
Participants usual insulin therapy with Freestyle Libre 3 glucose sensor
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CamAPS HX
The automated closed loop system (CamAPS HX) will consist of:
YpsoPump insulin pump Freestyle Libre 3 glucose sensor Smartphone hosting CamAPS HX app with the Cambridge model predictive control algorithm
Standard insulin therapy with glucose sensor
Participants usual insulin therapy with Freestyle Libre 3 glucose sensor
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Type 2 diabetes diagnosed for at least 12 months
* Established on an SGLT2 inhibitor and/or GLP-1 receptor agonist for at least 3 months, or have been offered these therapies previously.
* Treatment with insulin therapy for at least 6 months
* HbA1c ≤ 15% (140 mmol/mol) analysis from local laboratory or equivalent
* Willing to wear study devices and follow study instructions
* Capacity to consent to participate in the study
Exclusion Criteria
* Current use of insulin pump
* Current use of any closed-loop system
* Any physical/psychological disease or medication(s) likely to interfere with the conduct of the study and interpretation of the study results, as judged by study clinician
* Known or suspected allergy against insulin
* Medically documented allergy towards the adhesive
* Pregnancy, planned pregnancy, or breast feeding
* Severe visual impairment
* Severe hearing impairment
* Medically documented allergy towards the adhesive (glue) of plasters
* Serious skin diseases located at places of the body, which potentially are possible to be used for localisation of the glucose sensor
* Illicit drugs abuse
* Prescription drugs abuse
* Alcohol abuse
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Edinburgh
OTHER
Jaeb Center for Health Research
OTHER
Swansea University
OTHER
University of Cambridge
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr Roman Hovorka
Professor of Metabolic Technology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Roman Hovorka
Role: PRINCIPAL_INVESTIGATOR
University of Cambridge
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Melbourne
Melbourne, , Australia
Medical University of Graz
Graz, , Austria
Diabetes Centre, Institute of Clinical and Experimental Medicine
Prague, , Czechia
CHU de Toulouse
Toulouse, , France
Bern University Hospital
Bern, , Switzerland
Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust
Cambridge, , United Kingdom
Royal Derby Hospital
Derby, , United Kingdom
Leicester Diabetes Centre
Leicester, , United Kingdom
Guy's and St Thomas' NHS Foundation Trust
London, , United Kingdom
King's College Hospital, King's College NHS Foundation Trust
London, , United Kingdom
Manchester Royal Infirmary, Central Manchester University Hospitals NHS Foundation Trust
Manchester, , United Kingdom
Norfolk and Norwich University Hospital
Norwich, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
David O'Neal
Role: primary
Julia Mader
Role: primary
Martin Haluzík
Role: primary
Hélène Hanaire
Role: primary
Lia Bally
Role: primary
Charlotte Boughton
Role: primary
Emma Wilmot
Role: primary
Pratik Choudhary
Role: primary
Sufyan Hussain
Role: primary
Yee Cheah
Role: primary
Hood Thabit
Role: primary
Sankalpa Neupane
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
COYOTE
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.